1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 10,000 | 10,200 | 11:12 | |
| 9,850 | 10,100 | 11:13 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease | 248 | GlobeNewswire (Europe) | Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free... ► Artikel lesen | |
| 02.01. | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.12.25 | MiNK Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 20.11.25 | MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors | 1 | GlobeNewswire (USA) | ||
| 14.11.25 | MiNK Therapeutics GAAP EPS of -$0.65 beats by $0.20 | 2 | Seeking Alpha | ||
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.11.25 | MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation | 216 | GlobeNewswire (Europe) | New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive... ► Artikel lesen | |
| 07.11.25 | MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1-Refractory Solid Tumors at SITC 2025 | 221 | GlobeNewswire (Europe) | Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and tumor-immune... ► Artikel lesen | |
| 05.11.25 | MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development | 3 | GlobeNewswire (USA) | ||
| 30.10.25 | MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting | 3 | GlobeNewswire (USA) | ||
| 29.09.25 | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09.25 | MiNK Therapeutics appoints trauma expert Dr. John Holcomb to board | 2 | Investing.com | ||
| 29.09.25 | MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors | 11 | GlobeNewswire (USA) | ||
| 25.09.25 | MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA | 2 | GlobeNewswire (USA) | ||
| 18.09.25 | MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development | 1 | GlobeNewswire (USA) | ||
| 15.08.25 | MiNK Therapeutics stock rating upgraded to Buy by H.C. Wainwright on financial results | 4 | Investing.com | ||
| 14.08.25 | MiNK Therapeutics GAAP EPS of -$1.06 misses by $0.51 | 4 | Seeking Alpha | ||
| 14.08.25 | MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results | 227 | GlobeNewswire (Europe) | Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant... ► Artikel lesen | |
| 14.08.25 | MiNK Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.07.25 | XFRA 6Q40: WIEDERAUFNAHME/RESUMPTION | 362 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 11.07.25 | MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer | 177 | GlobeNewswire (Europe) | NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT)... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 50,80 | -0,97 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,030 | -3,71 % | Viking Therapeutics (VKTX) Soars 11.9% on Strong Weight Loss Market Outlook | ||
| NOVOCURE | 11,275 | -1,49 % | Assessing NovoCure: Insights From 4 Financial Analysts | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,750 | -0,34 % | Oxford Nanopore Tech - Share Incentive Plan - Director/PDMR Shareholding | ||
| MEREO BIOPHARMA | 0,534 | +1,14 % | MEREO BIOPHARMA zeigt klare innere Stärke | ||
| BIOLINERX | 2,225 | -14,09 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other... ► Artikel lesen | |
| ASSERTIO | 11,470 | +3,05 % | Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split | LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,081 | -4,80 % | Cycle Pharmaceuticals to Acquire Applied Therapeutics | NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT; "Applied"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare... ► Artikel lesen | |
| ROIVANT SCIENCES | 19,485 | -1,27 % | Roivant Sciences: Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day | Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three yearsHighlighting clinical execution... ► Artikel lesen | |
| REVOLUTION MEDICINES | 99,00 | -1,98 % | Revolution Medicines mit Rekordhoch: Steht die Mega-Übernahme kurz bevor? | Die viel beachtete JPMorgan Healthcare Conference ist bisher ohne größere Akquisitionen über die Bühne gegangen. Übernahmegerüchte um den Onkologie-Spezialisten Revolution Medicines halten sich indes... ► Artikel lesen | |
| AKERO THERAPEUTICS | 46,530 | -0,11 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 09.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 09.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 09.12.2025ISIN NameUS8581552036 STEELCASE... ► Artikel lesen | |
| ARVINAS | 12,200 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| JANUX THERAPEUTICS | 13,760 | +0,29 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| WEREWOLF THERAPEUTICS | 0,554 | 0,00 % | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer | Fast Track Designation underscores the promise of Werewolf's INDUKINE platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq:... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 8,640 | 0,00 % | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial | BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate... ► Artikel lesen |
Das Unternehmen MINK THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -8,08 % bei einem Aktienkurs von 9,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.